FLUPENTIXOL MELITRACEN COMBINED WITH ONDANSETRON IN PREVENTION OF NAUSEA AND VOMITING INDUCED BY CONDITIONING IN PATIENT TO UNDERGO HSCT
Author(s): ,
Ying Lu
Affiliations:
the third Affiliated Hospital of Sun Yat-Sen University,Guangzhou,China
,
Ruifang Fan
Affiliations:
the third Affiliated Hospital of Sun Yat-Sen University,Guangzhou,China
,
Lihua Kuang
Affiliations:
the third Affiliated Hospital of Sun Yat-Sen University,Guangzhou,China
,
Baoying Feng
Affiliations:
the third Affiliated Hospital of Sun Yat-Sen University,Guangzhou,China
Yuebin Shan
Affiliations:
the third Affiliated Hospital of Sun Yat-Sen University,Guangzhou,China
EHA Library. Lu Y. Jun 15, 2019; 267127; PS1510
Dr. Ying Lu
Dr. Ying Lu
Contributions
×
Abstract

Abstract: PS1510

Type: Poster Presentation

Presentation during EHA24: On Saturday, June 15, 2019 from 17:30 - 19:00

Location: Poster area

Background
Nausea and vomiting are the most common complaints for patients with haematological neoplasia during conditioning. The risk of hematopoiesis stem cell transplantation (HSCT) always cause people in anxiety and depression, which add patients’ discomforts. 

Aims
The aim of this study is to observe the effect of lupentixol melitracen combined with ondansetron on nausea and vomiting.

Methods
160 patients with hematological neoplasia in the state of complete remission were included in this study. The patients were randomly divided into control group and lupentixol melitracen group. For patients in control group, they received recommended-dose of ondansetron during conditioning each day. For patients in lupentixol melitracen group, they received lupentixol melitracen 10.5mg combined with ondansetron each day. The incidence of nausea and vomiting was evaluated before, during and after chemotherapeutics infusion in the first day of conditioning.

Results
Totally 158 patients, 78 in control group and 80 in lupentixol melitracen group could be evaluated. The difference of chemotherapy drug intensity in the two groups has no statistical significance (P > 0.05). The incidence of nausea before, during and immediately after chemotherapeutics infusion was respectively 5.2%, 72.5%, 60.6% in the control group and 1.6%, 53.3%, 45.5% in the lupentixol melitracen group, and the difference was significant between the two groups (P < 0.05). While the incidence of vomiting in the two groups has no significant difference (P > 0.05).

Conclusion
Flupentixol melitracen combined with ondansetron is more effective to prevent nausea than single ondansetron in patients during the first day of conditioning but no more effect on vomiting in our study.

Session topic: 35. Quality of life, palliative & supportive care, ethics and health economics

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies